BRIEF-Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients
ReutersFeb 26, 2025 12:51 PM
Feb 26 (Reuters) - Revelation Biosciences Inc REVB.O:
REVELATION BIOSCIENCES DOSES FIRST PATIENT IN PRIME PHASE 1B CLINICAL STUDY OF GEMINI IN CKD PATIENTS
REVELATION BIOSCIENCES INC - TOP-LINE DATA EXPECTED BY MID-YEAR
Source text: ID:nBw4fk9lga
Further company coverage: REVB.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
CoreWeave (CRWV): Is This AI Cloud Powerhouse the Smart Buy Right Now?
TradingKey - CoreWeave is a specialized AI infrastructure company delivering rapid access to advanced Nvidia GPUs and liquid-cooled clusters, with client demand exceeding current supply. Multi-year take-or-pay contracts and a large backlog underpin strong revenue growth, but results remain dependentTradingKey
an hour ago
Japan PM Ishiba Resigns, Yet Equities Rally — What’s Driving the Market?
TradingKey – On Sunday, Japanese Prime Minister Shigeru Ishiba unexpectedly announced his resignation. Despite the political shock, the Nikkei 225 surged, closing at 43,643 points — up more than 1.4%, after climbing as much as 1.88% intraday.TradingKey
an hour ago
U.S. August Nonfarm Payroll Preview: Risks Focus on Downward Revision of July Data
TradingKey - On 5 September 2025, the U.S. Department of Labour will release the August Non-Farm Payrolls report. The market widely expects August to see an addition of 75,000 non-farm jobs, roughly in line with July’s 73,000.TradingKey
Thu, Sep 4
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
US NFP Nightmares Preview: A Tiny August Revision, a Huge Annual Benchmark Cut And a Fed in Flux
TradingKey - Wall Street expects modest job growth and a rebound in the unemployment rate in August NFP report, a balanced outcome that could support a September rate cut. However, a massive downward revision — a “terrifying scene” — and anomalies on the supply side could plunge the Fed into deeperTradingKey
Wed, Sep 3
 (1).jpg)
Tradingkey
